Irish startup Cumulus Neuroscience has raised £3.25 million (US$4.4 million) to advance its NeuLogiq platform, which aims to improve neuroscience clinical trials using at-home EEG technology.

The platform features dry-sensor EEG headsets and tablet-based cognitive assessments, developed with input from 10 biopharma companies.

The FDA cleared the EEG headset in 2023 for clinical and home use, making it especially useful for studying hard-to-assess conditions like Alzheimer’s.

The funding round was led by Whiterock’s Growth Capital Fund with £1.5 million (US$2 million).

Cumulus Neuroscience plans to use the funds to boost its marketing efforts and expand its team, including hiring for senior roles in marketing, sales operations, and business development.

🔗 Source: Tech.eu

🧠 Food for thought

1️⃣ EEG’s century-long journey from clinical tool to home-based solution

EEG technology has undergone a remarkable evolution since Hans Berger recorded the first human brainwaves in 1924, transforming from a hospital-based diagnostic tool to today’s portable, home-friendly solutions 1.

Traditional EEG systems required specialized technicians and clinical settings, creating barriers for extended monitoring and limiting their use in pharmaceutical research for neurological conditions.

The development of dry-sensor technology, like that used in Cumulus’s FDA-cleared headset, represents a significant technological breakthrough that eliminates the need for conductive gels that made traditional EEG impractical outside clinical environments 2.

This shift toward home-based monitoring addresses a critical challenge in neuroscience drug development, where capturing real-world brain activity over extended periods provides more representative data than brief in-clinic sessions.

Neurotech has already demonstrated the effectiveness of home-based EEG monitoring, showing that patients benefit from being in comfortable environments while still providing quality data for clinical assessment 3.

2️⃣ Neuroscience startups are fueling a biomarker revolution in CNS drug development

The neuroscience market’s projected growth to $721 billion by 2026 reflects massive investment in addressing the unmet needs of nearly one billion people worldwide suffering from neurological disorders 4.

Cumulus joins a wave of neurotechnology companies leveraging EEG as more than just a diagnostic tool—they’re mining it for biomarkers that can validate drug efficacy and accelerate clinical trials for conditions that have historically seen high failure rates.